Junk DNA, and a clue to Alzheimer's
In the 18 December issue of Nature Neuroscience, a team from UNSW reports a link between the non-coding genome, the stretch once dismissed as junk DNA, and Alzheimer’s disease, finding that variants outside the genes shape the disease through their effects on the brain’s support cells. The 98 per cent of the genome that does not code for proteins is increasingly hard to ignore.
For decades, a large fraction of the human genome was described with a phrase that has aged badly: junk DNA. The label was shorthand for the roughly ninety-eight per cent of the genome that does not code for proteins, the long stretches whose function was unknown and whose importance was doubted. The doubts have been eroding for years, as studies have tied non-coding regions to gene regulation, development and disease. A paper in the 18 December issue of Nature Neuroscience adds a major chapter to that revision, reporting a link between the non-coding genome and Alzheimer’s disease, and identifying the brain’s support cells, the glia, as the stage on which the connection plays out.
The study, from a team at UNSW, examined how genetic variants in non-coding regions influence the risk of Alzheimer’s. The disease has a well-known genetic architecture, with coding variants in a handful of genes carrying clear risk, but the full picture has always been larger: genome-wide studies have pointed at many more locations, and most of those fall outside the genes. The question has been what those locations do. The new work connects them to the regulatory machinery of the brain’s support cells, showing that non-coding variants alter how those cells behave, and through them, the processes that lead to the disease.
The focus on glia is itself a shift in the field’s centre of gravity. Alzheimer’s research long concentrated on neurons, the cells that die in the disease, but the support cells have moved to the centre of the story in recent years: the microglia that clear debris, the astrocytes that maintain the environment around neurons, all of them are now understood as active participants rather than bystanders. The new paper’s contribution is to show that the genetic risk concentrated in the non-coding genome acts through exactly these cells, giving the non-coding signal a mechanism rather than leaving it as a statistical trace.
The paper is careful about what it claims, and the carefulness is appropriate. The link between non-coding variants, glial behaviour and Alzheimer’s risk is strong in the study’s analyses, but translating such findings into understanding, let alone therapy, is a long road, and the authors do not pretend otherwise. The significance is in the architecture of the result: it fills in, for one major disease, the question that has shadowed genetics for a generation, which is what the non-coding genome is actually for.
The wider lesson is the quiet overturning of the old label. Junk DNA was always a confession of ignorance dressed as a conclusion, and study after study has been converting its stretches into functional territory: regulators, switches, structural elements, and now, contributors to one of the most burdensome diseases of ageing. The genome’s non-coding majority is not junk; it is the control layer, and the more we learn about disease, the more the controls turn out to matter. The 98 per cent has been listening all along, and Alzheimer’s is among the places where its voice is finally being heard.